CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 138 enrolled
Drug / intervention
Sugammadex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03420937
NCT03420937Phase 4Completed
CompareCT.gov

Deep Neuromuscular Block During General Anaesthesia in Laparoscopic (and Robotic Laparoscopic) Surgery and Its Potential Benefits for Certain Physiological Parameters in Perioperative Period

University Hospital Olomouc·interventional·Posted Feb 5, 2018·Updated Feb 5, 2018

In Brief

A Phase 4 clinical trial evaluating Sugammadex and Neostigmine, Atropin Biotika for Observation of Neuromuscular Block and 2 related conditions. Completed, enrolled 138 participants across 1 site.

Detailed Summary

The aim of this project is to show, whether the use of the deep neuromuscular block in certain laparoscopic robot-assisted surgery can positively influence main physiological functions compared to the use of standard neuromuscular block. Secondary outcome is to find out whether the targeted specific reversal of neuromuscular block by sugammadex improves and fastens the post-operative recovery of the patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObservation of Neuromuscular Block, Complication of Ventilation Therapy, Postoperative Recovery
CountriesCzechia
CollaboratorsPalacky University

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 5, 2018
Enrollment StartJun 1, 2016
Primary CompletionJun 1, 2017
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 8.4 years ago

Interventions

Sugammadexdrug

Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.

Neostigmine, Atropin Biotikadrug

Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.